Filing exhibits
- 8-K Current report
- 1.1 Underwriting Agreement, Dated January 19, 2023, by and Between Cadrenal Therapeutics, Inc. and Boustead Securities, LLC
- 4.1 Representative's Warrant Issued to Boustead Securities, LLC, Dated January 19, 2023
- 10.1 Form of Indemnification Agreement
- 10.2 Amendment to Asset Purchase Agreement, Dated As of August 18, 2022, Between the Company and Hesp LLC
- 10.3 Employment Agreement, Dated January 24, 2023, by and Between Cadrenal Therapeutics, Inc. and Matthew Szot
- 10.4 Employment Agreement, Effective As of January 24, 2023, by and Between Cadrenal Therapeutics, Inc. and Douglas Losordo
- 99.1 Press Release Announcing Pricing of Ipo, Dated January 20, 2023
- 99.2 Press Release Announcing Fast Track Designation for Tecarfarin, Dated January 23, 2023
- 99.3 Press Release Announcing Closing of Ipo, Dated January 24, 2023
- Download Excel data file
- View Excel data file
Table of Contents